Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hy… Read more
Ind-Swift Laboratories Limited (INDSWFTLAB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.015x
Based on the latest financial reports, Ind-Swift Laboratories Limited (INDSWFTLAB) has a cash flow conversion efficiency ratio of -0.015x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹-202.50 Million) by net assets (₹13.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ind-Swift Laboratories Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Ind-Swift Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ind-Swift Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ind-Swift Laboratories Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Turnkey Communication Services PCL
BK:TKC
|
-0.028x |
|
SYGNITY S.A. ZY 1
F:CPN
|
N/A |
|
MNC Vision Networks PT
JK:IPTV
|
0.015x |
|
Embellence Group AB
ST:EMBELL
|
0.059x |
|
Origin Property PCL
BK:ORI
|
0.023x |
|
RLAIF
OTCQB:RLAIF
|
3.692x |
|
Propdo Ltd
TA:PRPD
|
-0.899x |
|
Diamond Building Products Public Company Limited
BK:DRT
|
0.054x |
Annual Cash Flow Conversion Efficiency for Ind-Swift Laboratories Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Ind-Swift Laboratories Limited from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹11.73 Billion | ₹-254.74 Million | -0.022x | +89.19% |
| 2024-03-31 | ₹8.12 Billion | ₹-1.63 Billion | -0.201x | -170.38% |
| 2023-03-31 | ₹6.82 Billion | ₹1.95 Billion | 0.285x | +14.11% |
| 2022-03-31 | ₹6.01 Billion | ₹1.50 Billion | 0.250x | +11.83% |
| 2021-03-31 | ₹6.03 Billion | ₹1.35 Billion | 0.224x | +14.40% |
| 2020-03-31 | ₹6.41 Billion | ₹1.25 Billion | 0.195x | +278.44% |
| 2019-03-31 | ₹5.88 Billion | ₹-644.00 Million | -0.110x | -182.93% |
| 2018-03-31 | ₹5.53 Billion | ₹730.90 Million | 0.132x | -26.55% |
| 2017-03-31 | ₹5.31 Billion | ₹955.66 Million | 0.180x | +17.17% |
| 2016-03-31 | ₹5.17 Billion | ₹794.30 Million | 0.154x | -7.25% |
| 2015-03-31 | ₹5.95 Billion | ₹983.98 Million | 0.166x | +83.17% |
| 2014-03-31 | ₹7.25 Billion | ₹655.29 Million | 0.090x | +265.47% |
| 2013-03-31 | ₹8.53 Billion | ₹-466.03 Million | -0.055x | -161.11% |
| 2012-03-31 | ₹8.12 Billion | ₹725.24 Million | 0.089x | +193.19% |
| 2011-03-31 | ₹5.84 Billion | ₹177.83 Million | 0.030x | -69.08% |
| 2010-03-31 | ₹4.48 Billion | ₹441.84 Million | 0.099x | -64.25% |
| 2009-03-31 | ₹3.63 Billion | ₹1.00 Billion | 0.276x | +61.91% |
| 2008-03-31 | ₹3.33 Billion | ₹567.77 Million | 0.170x | +17.18% |
| 2007-03-31 | ₹3.11 Billion | ₹452.62 Million | 0.145x | +137.58% |
| 2006-03-31 | ₹1.92 Billion | ₹117.63 Million | 0.061x | -- |